Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Mesoblast Limited (MESO : NSDQ)
 
 • Company Description   
Mesoblast Limited is a global leader in developing innovative cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast's allogeneic, 'off-the-shelf' cell product candidates target advanced stages of diseases with high, unmet medical needs including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions.

Number of Employees: 83

 
 • Price / Volume Information   
Yesterday's Closing Price: $3.58 Daily Weekly Monthly
20 Day Moving Average: 61,136 shares
Shares Outstanding: 130.09 (millions)
Market Capitalization: $465.73 (millions)
Beta: 3.05
52 Week High: $8.85
52 Week Low: $3.23
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -10.50% 0.81%
12 Week -8.91% 0.15%
Year To Date -25.42% -8.87%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
LEVEL 38 55 COLLINS STREET
-
MELBOURNE,C3 3000
AUS
ph: 61-3-9639-6036
fax: 61-3-9639-6030
schond.greenway@mesoblast.com http://www.mesoblast.com
 
 • General Corporate Information   
Officers
Silviu Itescu - Chief Executive Officer
Joseph R Swedish - Chairman
Josh Muntner - Chief Financial Officer
Donal O'Dwyer - Director
Michael Spooner - Director

Peer Information
Mesoblast Limited (CORR.)
Mesoblast Limited (RSPI)
Mesoblast Limited (CGXP)
Mesoblast Limited (BGEN)
Mesoblast Limited (GTBP)
Mesoblast Limited (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 590717104
SIC: 2836
Fiscal Year
Fiscal Year End: June
Last Reported Quarter: 12/01/21
Next Expected EPS Date: 06/01/22
Share - Related Items
Shares Outstanding: 130.09
Most Recent Split Date: (:1)
Beta: 3.05
Market Capitalization: $465.73 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.05 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.49 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 06/01/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.87
Price/Cash Flow: -
Price / Sales: 47.10
EPS Growth
vs. Year Ago Period: 9.09%
vs. Previous Quarter: -17.65%
Sales Growth
vs. Year Ago Period: 6.34%
vs. Previous Quarter: -33.70%
ROE
03/31/22 - -
12/31/21 - -17.07
09/30/21 - -17.15
ROA
03/31/22 - -
12/31/21 - -13.23
09/30/21 - -13.28
Current Ratio
03/31/22 - -
12/31/21 - 1.88
09/30/21 - 1.36
Quick Ratio
03/31/22 - -
12/31/21 - 1.88
09/30/21 - 1.36
Operating Margin
03/31/22 - -
12/31/21 - -982.76
09/30/21 - -994.48
Net Margin
03/31/22 - -
12/31/21 - -982.76
09/30/21 - -994.48
Pre-Tax Margin
03/31/22 - -
12/31/21 - -985.84
09/30/21 - -996.03
Book Value
03/31/22 - -
12/31/21 - 4.12
09/30/21 - 4.31
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - -
12/31/21 - 0.16
09/30/21 - 0.08
Debt-to-Capital
03/31/22 - -
12/31/21 - 13.91
09/30/21 - 7.08
 

Powered by Zacks Investment Research ©